Skip to content
2000
Volume 16, Issue 29
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Phosphodiesterases (PDEs) have gained attention as potential pharmacological targets for neuropsychiatric diseases due to their ability to hydrolyze the second messengers, cGMP and/or cAMP. It is well-known the relationship between cAMP signaling and inflammation. Since neuroinflammation is considered to play an important role in the pathology of brain disorders, inhibition of PDEs highly expressed in brain has emerged as an innovative strategy for the treatment of these pathologies. PDE4, 7, 8 and 10 inhibitors are presented here as promising drug candidates to overcome the partial efficacy and adverse effects of the current therapy for neuropsychiatric illness such as depression, cognitive impairments or schizophrenia. Enhancing the intracellular concentration of cAMP underlies the effects of PDE inhibitors in the above mentioned disorders.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026616666160426151306
2016-12-01
2024-12-23
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026616666160426151306
Loading

  • Article Type:
    Research Article
Keyword(s): cAMP; Cognitive Impairment; Depression; inhibitors; Phosphodiesterase; Schizophrenia
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test